Close Menu

NEW YORK – In Step 1 of the Phase III Atalante 1 trial, OSE Immunotherapeutics' investigational agent Tedopi improved the 12-month survival rate over chemotherapy in patients with HLA-A2 positive non-small cell lung cancer who failed PD-1 or PD-L1 immune checkpoint inhibitor therapy. 

The preliminary data show that in the Tedopi arm of the trial, the 12-month survival rate was 46 percent compared to 36 percent in the chemotherapy arm.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.